# Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer

Source: https://onco.cc/trials/nct06830239/  
OnCo record `nct06830239` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of dostarlimab in colorectal cancer, run by Universitaire Ziekenhuizen KU Leuven, now recruiting.

## Summary

Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer is a phase 2, interventional study registered as NCT06830239 by Universitaire Ziekenhuizen KU Leuven, with a registry enrolment figure of 10 participants, started 2025-04-03 and due to reach its primary completion in 2027-12. Interventions recorded: Dostarlimab. Conditions listed: Colon Cancer Stage III. Primary outcome: Multi-omic exploration. Colorectal eligibility wording from the registry: "* primary adenocarcinoma colon cancer than can be removed surgically, staged cT3-4, cN0-2, cM0 or stage III". Sites: Belgium. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: Superhero
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06830239
- Phase: 2
- Setting: Early Phase II Exploratory, Open-Label, Non-Randomized Study of Neoadjuvant Dostarlimab Monotherapy in Participants With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer
- Sponsor: Universitaire Ziekenhuizen KU Leuven
- Enrolled: 10

## Sources

- ClinicalTrials.gov NCT06830239: https://clinicaltrials.gov/study/NCT06830239

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Dostarlimab](https://onco.cc/drugs/dostarlimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06830239.json